ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.
Kristine Peregrino Lacuna(Memorial Sloan Kettering Cancer Center), Matthew Ingham(Columbia University), Gary K. Schwartz(Baylor University Medical Center), Mia C. Weiss(Washington University in St. Louis), Brittany L. Siontis(Mayo Clinic in Arizona), Mark Agulnik(Northwestern University), Shing M. Lee(Columbia University), Gina Z. D’Amato(University of Miami Health System), Tahir Sheikh(Herbert Irving Comprehensive Cancer Center), Richard Piekarz(Yeshiva University), Mary Louise Keohan(Roche (Switzerland)), Mihaela Druta(Moffitt Cancer Center), Mahesh Seetharam(Mayo Clinic in Arizona), Melissa Burgess(University of Pittsburgh Medical Center), Anthony P. Conley(The University of Texas MD Anderson Cancer Center), Benjamin Powers(University of Kansas Medical Center), Sminu Bose(Memorial Sloan Kettering Cancer Center), A. Chalmers(University of Utah), Liner Ge(Columbia University)
Cited by 1
Related Papers
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
|Journal of Clinical Oncology|2005|1.1k
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
|Nature Genetics|2010|725
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
|Journal of Clinical Oncology|2009|573